Wanstall J C, Kay C S, O'Donnell S R
Department of Physiology and Pharmacology, University of Queensland, Brisbane, Australia.
Pulm Pharmacol. 1994 Dec;7(6):401-8. doi: 10.1006/pulp.1994.1047.
Vasorelaxant responses to the potassium channel opening drug, pinacidil, were obtained on preparations of pulmonary artery and aorta taken from rats with pulmonary hypertension (induced by chronic hypoxia or monocrotaline) and pre-contracted either submaximally with endothelin-1 (ET-1), PGF2 alpha, U46619 (thromboxane-mimetic) or noradrenaline (NA), or with 80 mM K+. In pulmonary artery, but not aorta, from pulmonary hypertensive rats the maximum relaxant response to pinacidil was increased, when compared with data in control rats, irrespective of the spasmogen used to precontract the tissues. The increase in maximum was associated with relaxation to below the tissue resting baseline and probably reflected the presence of inherent contractile tone in arteries from pulmonary hypertensive rats. In addition the potency (-log EC50) of pinacidil was increased in pulmonary arteries from pulmonary hypertensive rats but this was seen only in preparations contracted with ET-1 (30-fold increase) or NA (seven-fold increase) and not in those contracted with PGF2 alpha, U46619 or K+. As a result, in ET-1 contracted preparations from pulmonary hypertensive rats pinacidil was 29-fold more potent on pulmonary artery than on aorta. To explain the increase in potency it is speculated that during the development of pulmonary hypertension the mechanism whereby ET-1 and NA contract pulmonary arteries may change from one in which Ca2+ influx plays only a minor role to one in which Ca2+ influx predominates, although no direct evidence to support this speculation has yet been obtained.
在取自患有肺动脉高压(由慢性低氧或野百合碱诱导)大鼠的肺动脉和主动脉制备物上,获得了对钾通道开放药物吡那地尔的血管舒张反应。这些制备物预先用内皮素-1(ET-1)、前列腺素F2α、U46619(血栓素类似物)或去甲肾上腺素(NA)进行亚最大收缩,或用80 mM钾进行收缩。与对照大鼠的数据相比,在肺动脉高压大鼠的肺动脉而非主动脉中,无论用于预先收缩组织的痉挛原是什么,对吡那地尔的最大舒张反应均增加。最大反应的增加与舒张至组织静息基线以下有关,可能反映了肺动脉高压大鼠动脉中存在固有收缩张力。此外,吡那地尔在肺动脉高压大鼠肺动脉中的效价(-log EC50)增加,但仅在与ET-1(增加30倍)或NA(增加7倍)收缩的制备物中可见,而在与前列腺素F2α、U46619或钾收缩的制备物中未见。结果,在肺动脉高压大鼠ET-1收缩的制备物中,吡那地尔对肺动脉的效价比主动脉高29倍。为了解释效价的增加,推测在肺动脉高压发展过程中,ET-1和NA收缩肺动脉的机制可能从Ca2+内流仅起次要作用的机制转变为Ca2+内流占主导的机制,尽管尚未获得支持这一推测的直接证据。